Mirum Pharmaceuticals Stock Alpha and Beta Analysis
| MIRM Stock | USD 48.30 1.58 3.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mirum Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mirum Pharmaceuticals over a specified time horizon. Remember, high Mirum Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mirum Pharmaceuticals' market risk premium analysis include:
Beta 0.64 | Alpha 0.25 | Risk 2.52 | Sharpe Ratio 0.15 | Expected Return 0.37 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Mirum |
Mirum Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mirum Pharmaceuticals market risk premium is the additional return an investor will receive from holding Mirum Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mirum Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mirum Pharmaceuticals' performance over market.| α | 0.25 | β | 0.64 |
Mirum Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Mirum Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Mirum Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Mirum Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Mirum Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mirum Pharmaceuticals shares will generate the highest return on investment. By understating and applying Mirum Pharmaceuticals stock market price indicators, traders can identify Mirum Pharmaceuticals position entry and exit signals to maximize returns.
Mirum Pharmaceuticals Return and Market Media
The median price of Mirum Pharmaceuticals for the period between Fri, Oct 25, 2024 and Thu, Jan 23, 2025 is 42.17 with a coefficient of variation of 5.64. The daily time series for the period is distributed with a sample standard deviation of 2.4, arithmetic mean of 42.54, and mean deviation of 1.97. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting | 11/14/2024 |
2 | Mirum Pharmaceuticals Announces Inducement Awards for New Employees | 12/11/2024 |
3 | Acquisition by Longpre Lara of 434 shares of Mirum Pharmaceuticals at 22.287 subject to Rule 16b-3 | 12/19/2024 |
4 | Disposition of 1250 shares by Howe Jolanda of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/06/2025 |
5 | Disposition of 750 shares by Howe Jolanda of Mirum Pharmaceuticals at 42.8153 subject to Rule 16b-3 | 01/07/2025 |
6 | Disposition of 1379 shares by Pamela Vig of Mirum Pharmaceuticals at 20.6223 subject to Rule 16b-3 | 01/08/2025 |
7 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/10/2025 |
8 | Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates | 01/13/2025 |
9 | Mirum Pharmaceuticals Is a Great Choice for Trend Investors, Heres Why | 01/14/2025 |
10 | Disposition of 6969 shares by Quan Joanne of Mirum Pharmaceuticals at 45.86 subject to Rule 16b-3 | 01/17/2025 |
About Mirum Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mirum or other stocks. Alpha measures the amount that position in Mirum Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 1.42 | 6.34 | 5.71 | 5.99 | Days Of Inventory On Hand | 164.15 | 173.13 | 199.1 | 230.08 |
Mirum Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Mirum Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mirum Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mirum Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mirum Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Mirum Pharmaceuticals' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Mirum Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Mirum Pharmaceuticals Backtesting, Mirum Pharmaceuticals Valuation, Mirum Pharmaceuticals Correlation, Mirum Pharmaceuticals Hype Analysis, Mirum Pharmaceuticals Volatility, Mirum Pharmaceuticals History and analyze Mirum Pharmaceuticals Performance. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Mirum Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.